Compare GRPN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | OMER |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | 1734 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.1M | 772.8M |
| IPO Year | 2011 | 2008 |
| Metric | GRPN | OMER |
|---|---|---|
| Price | $17.75 | $9.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $33.67 | $32.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $2,843,877,000.00 | $29,868,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.63 | $233.22 |
| P/E Ratio | ★ N/A | $14.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.17 | $2.95 |
| 52 Week High | $41.26 | $17.65 |
| Indicator | GRPN | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 32.25 |
| Support Level | $16.05 | $8.27 |
| Resistance Level | $18.81 | $12.06 |
| Average True Range (ATR) | 1.43 | 0.79 |
| MACD | -0.32 | -0.11 |
| Stochastic Oscillator | 32.65 | 49.45 |
Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.